Adaptive Biotechnologies (ADPT)
(Real Time Quote from BATS)
$14.50 USD
+0.12 (0.83%)
Updated Oct 6, 2025 03:38 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Adaptive Biotechnologies Corporation has a PEG ratio of 1.18 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.09.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADPT 14.50 +0.12(0.83%)
Will ADPT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
Other News for ADPT
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade)
ADPT forms Upper Bollinger Band Walk on October 3
Is ADPT poised for gains? Slingshot Bullish shows up after slipping 0.76%
Is ADPT set to rally? New 52 Week High shows up after declining 2.67%
Is ADPT positioned for a breakout? New 52 Week Closing High shows up after surging 11.14%